Market news

Detailed price information for Exagen Inc (XGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Exagen Inc (XGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

Detailed price information for Exagen Inc (XGN-Q) from The Globe and Mail including charting and trades.

Moby summary of Exagen Inc.'s Q2 2026 earnings call

Exagen Inc (XGN) reports record Q2 revenue of $19.9 million, nearly achieving adjusted EBITDA breakeven, and raises full-year guidance.

Exagen (NASDAQ:XGN) reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even. Revenue for the quarter ended June 30 rose 16% year over year and 15% sequ

Exagen (NASDAQ:XGN) delivered record quarterly revenue, narrowed losses, improved adjusted EBITDA, and increased its full-year revenue outlook as demand for its autoimmune testing portfolio continued to grow. Key Investor TakeawaysExagen (NASDAQ:XGN) reported record second-quarter revenue of $19.

Exagen (XGN) delivered earnings and revenue surprises of +31.58% and +10.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates. Three Months Ended June 30, Six Months Ended June 30, 202

CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord Genuity 46th Annual Growth Conference – Boston, MADate: August 11, 2026Fireside Chat at 8:30am ETA live and archived webcast of the Fireside Chat will be available on Exagen’s Investor Relations website at investors.exagen.com. About Exagen Inc.Exagen Inc. (Nasdaq: XGN) is a leadin

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) that morning to review the Company’s results. Conference Call and Webcast: U.S. dial-in: 877-407